Freddyd
2021-07-22
Ooo
Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO<blockquote>华平投资支持的人工智能药物公司Insilico考虑在美国IPO</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":172380975,"tweetId":"172380975","gmtCreate":1626935856697,"gmtModify":1633769573532,"author":{"id":3574854386909318,"idStr":"3574854386909318","authorId":3574854386909318,"authorIdStr":"3574854386909318","name":"Freddyd","avatar":"https://static.tigerbbs.com/7967e4125926fdf32d9965f6fe32519d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ooo</p></body></html>","htmlText":"<html><head></head><body><p>Ooo</p></body></html>","text":"Ooo","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/172380975","repostId":1157055369,"repostType":4,"repost":{"id":"1157055369","kind":"news","pubTimestamp":1626932797,"share":"https://www.laohu8.com/m/news/1157055369?lang=zh_CN&edition=full","pubTime":"2021-07-22 13:46","market":"us","language":"en","title":"Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO<blockquote>华平投资支持的人工智能药物公司Insilico考虑在美国IPO</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157055369","media":"Bloomberg","summary":"(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discover","content":"<p>(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.</p><p><blockquote>（彭博社）——据知情人士透露，利用人工智能推动药物发现的公司Insilico Medicine正在考虑在美国进行首次公开募股，可能筹集约3亿美元。</blockquote></p><p> The Hong Kong-based firm is in talks with investment banks about a possible first-time share sale as soon as later this year, the people said, asking not to be identified because the matter is private.</p><p><blockquote>知情人士称，这家总部位于香港的公司正在与投资银行就最早可能在今年晚些时候首次出售股票进行谈判。由于此事属于私人性质，因此要求匿名。</blockquote></p><p> No final decisions have been made and details such as size, timing and venue could change, the people said. Insilico could also opt to do another private funding round, they said.</p><p><blockquote>知情人士称，尚未做出最终决定，规模、时间和地点等细节可能会发生变化。他们表示，Insilico还可以选择进行另一轮私人融资。</blockquote></p><p> Insilico founder and Chief Executive Officer Alex Zhavoronkov declined to comment.</p><p><blockquote>Insilico创始人兼首席执行官Alex Zhavoronkov拒绝置评。</blockquote></p><p> Founded in 2014, Insilico works with pharmaceutical and biotechnology companies and uses AI to help improve their research and development capabilities, according to its website. The firm’s technology has helped generate drug candidates and complete pre-clinical studies to treat a pulmonary disease. Its partners include U.S. pharma giants Pfizer Inc. and Johnson & Johnson, and Japanese drugmakers Astellas Pharma Inc. and Taisho Pharmaceutical Holdings Co.</p><p><blockquote>Insilico成立于2014年，据其网站称，它与制药和生物技术公司合作，并使用人工智能来帮助提高他们的研发能力。该公司的技术帮助产生了候选药物并完成了治疗肺部疾病的临床前研究。其合作伙伴包括美国制药巨头辉瑞公司和强生公司，以及日本制药商安斯泰来制药公司和大正制药控股公司。</blockquote></p><p> The company has also partnered with Syngenta Group, the Swiss seed and fertilizer business owned by China National Chemical Corp., on the discovery of novel molecules for sustainable regenerative farming.</p><p><blockquote>该公司还与中国化工集团公司旗下的瑞士种子和化肥企业先正达集团合作，发现用于可持续再生农业的新分子。</blockquote></p><p> Insilico raised $255 million in June in a series C financing led by private equity firm Warburg Pincus. Existing investors including Qiming Venture Partners and Baidu Ventures, the venture capital arm of Chinese search giant Baidu Inc., also participated in the round. OrbiMed, Mirae Asset Capital and Sequoia Capital China are among the new backers.</p><p><blockquote>Insilico于6月份在私募股权公司Warburg Pincus领投的C轮融资中筹集了2.55亿美元。包括启明创投（Chiming Venture Partners）和百度风投（China Ventures）在内的现有投资者也参与了本轮融资。OrbiMed、Mirae Asset Capital和红杉资本中国是新的支持者。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO<blockquote>华平投资支持的人工智能药物公司Insilico考虑在美国IPO</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO<blockquote>华平投资支持的人工智能药物公司Insilico考虑在美国IPO</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-07-22 13:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.</p><p><blockquote>（彭博社）——据知情人士透露，利用人工智能推动药物发现的公司Insilico Medicine正在考虑在美国进行首次公开募股，可能筹集约3亿美元。</blockquote></p><p> The Hong Kong-based firm is in talks with investment banks about a possible first-time share sale as soon as later this year, the people said, asking not to be identified because the matter is private.</p><p><blockquote>知情人士称，这家总部位于香港的公司正在与投资银行就最早可能在今年晚些时候首次出售股票进行谈判。由于此事属于私人性质，因此要求匿名。</blockquote></p><p> No final decisions have been made and details such as size, timing and venue could change, the people said. Insilico could also opt to do another private funding round, they said.</p><p><blockquote>知情人士称，尚未做出最终决定，规模、时间和地点等细节可能会发生变化。他们表示，Insilico还可以选择进行另一轮私人融资。</blockquote></p><p> Insilico founder and Chief Executive Officer Alex Zhavoronkov declined to comment.</p><p><blockquote>Insilico创始人兼首席执行官Alex Zhavoronkov拒绝置评。</blockquote></p><p> Founded in 2014, Insilico works with pharmaceutical and biotechnology companies and uses AI to help improve their research and development capabilities, according to its website. The firm’s technology has helped generate drug candidates and complete pre-clinical studies to treat a pulmonary disease. Its partners include U.S. pharma giants Pfizer Inc. and Johnson & Johnson, and Japanese drugmakers Astellas Pharma Inc. and Taisho Pharmaceutical Holdings Co.</p><p><blockquote>Insilico成立于2014年，据其网站称，它与制药和生物技术公司合作，并使用人工智能来帮助提高他们的研发能力。该公司的技术帮助产生了候选药物并完成了治疗肺部疾病的临床前研究。其合作伙伴包括美国制药巨头辉瑞公司和强生公司，以及日本制药商安斯泰来制药公司和大正制药控股公司。</blockquote></p><p> The company has also partnered with Syngenta Group, the Swiss seed and fertilizer business owned by China National Chemical Corp., on the discovery of novel molecules for sustainable regenerative farming.</p><p><blockquote>该公司还与中国化工集团公司旗下的瑞士种子和化肥企业先正达集团合作，发现用于可持续再生农业的新分子。</blockquote></p><p> Insilico raised $255 million in June in a series C financing led by private equity firm Warburg Pincus. Existing investors including Qiming Venture Partners and Baidu Ventures, the venture capital arm of Chinese search giant Baidu Inc., also participated in the round. OrbiMed, Mirae Asset Capital and Sequoia Capital China are among the new backers.</p><p><blockquote>Insilico于6月份在私募股权公司Warburg Pincus领投的C轮融资中筹集了2.55亿美元。包括启明创投（Chiming Venture Partners）和百度风投（China Ventures）在内的现有投资者也参与了本轮融资。OrbiMed、Mirae Asset Capital和红杉资本中国是新的支持者。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/warburg-pincus-backed-ai-drug-035541170.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WPCA":"Warburg Pincus Capital I-A Corp"},"source_url":"https://finance.yahoo.com/news/warburg-pincus-backed-ai-drug-035541170.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157055369","content_text":"(Bloomberg) -- Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.\nThe Hong Kong-based firm is in talks with investment banks about a possible first-time share sale as soon as later this year, the people said, asking not to be identified because the matter is private.\nNo final decisions have been made and details such as size, timing and venue could change, the people said. Insilico could also opt to do another private funding round, they said.\nInsilico founder and Chief Executive Officer Alex Zhavoronkov declined to comment.\nFounded in 2014, Insilico works with pharmaceutical and biotechnology companies and uses AI to help improve their research and development capabilities, according to its website. The firm’s technology has helped generate drug candidates and complete pre-clinical studies to treat a pulmonary disease. Its partners include U.S. pharma giants Pfizer Inc. and Johnson & Johnson, and Japanese drugmakers Astellas Pharma Inc. and Taisho Pharmaceutical Holdings Co.\nThe company has also partnered with Syngenta Group, the Swiss seed and fertilizer business owned by China National Chemical Corp., on the discovery of novel molecules for sustainable regenerative farming.\nInsilico raised $255 million in June in a series C financing led by private equity firm Warburg Pincus. Existing investors including Qiming Venture Partners and Baidu Ventures, the venture capital arm of Chinese search giant Baidu Inc., also participated in the round. OrbiMed, Mirae Asset Capital and Sequoia Capital China are among the new backers.","news_type":1,"symbols_score_info":{"WPCA":0.9}},"isVote":1,"tweetType":1,"viewCount":2987,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/172380975"}
精彩评论